How to buy BioNTech shares | $93.92

BioNTech SE is a biotechnology business with stocks listed in the US. BioNTech shares (BNTX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was US$93.92 – an increase of 0.99% over the previous week.

How to buy shares in BioNTech

1. Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
3. Search for BioNTech. Find the share by name or ticker symbol: BNTX. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until BioNTech reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of US$93.92, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of BioNTech, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of BioNTech. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

🧪How we chose these brokers

For our Top Picks, we compared our Finder partners using a proprietary algorithm in August 2020. Keep in mind that our top picks may not always be the best for you, and you're encouraged to compare for yourself to find one that works for you. Read our full methodology here to find out more.

How has coronavirus impacted BioNTech's share price?

Since the stock market crash in March caused by coronavirus, BioNTech's share price has had significant positive movement.

Its last market close was US$93.92, which is 65.56% up on its pre-crash value of US$32.35 and 235.43% up on the lowest point reached during the March crash when the shares fell as low as US$28.

If you had bought US$1,000 worth of BioNTech shares at the start of February 2020, those shares would have been worth US$1,695.28 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth US$3,103.12.

BioNTech share price

Use our graph to track the performance of BNTX stocks over time.

BioNTech shares at a glance

• Key figures

Information last updated 2020-10-20.

Latest market close	USD$93.92
52-week range	USD$16.12 - USD$104.99
50-day moving average	USD$72.3891
200-day moving average	USD$63.4096
Target price	USD$80.68
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-0.5631

Get $0 brokerage on US stocks with trades as little as $50 when you join the world’s biggest social trading network.

eToro Share Trading (US stocks)

USD 0

Standard brokerage - US shares

Get $0 brokerage on US stocks with trades as little as $50 when you join the world’s biggest social trading network.

• $0 brokerage for US stocks
• Trades starting from $50
• Fractional shares
• Copy top traders

Go to site

More info

Important: Share trading carries risk of capital loss.

Compare share trading platforms

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.

Is it a good time to buy BioNTech stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of BioNTech SE by TradingView

BioNTech price performance over time

Historical closes compared with the close of $93.92 on 2020-10-19

1 week (2020-10-22)	8.75%
1 month (2020-09-29)	40.47%
3 months (2020-07-29)	13.84%
6 months (2020-04-29)	90.70%

1 year (2019-10-29)	452.47%
2 years (2018-10-25)	N/A
3 years (2017-10-25)	N/A
5 years (2015-10-25)	N/A

BioNTech financials

Gross profit TTM	US$91.2 million
Return on assets TTM	-16.96%
Return on equity TTM	-46.64%
Profit margin	-182.44%
Book value	N/A
Market capitalisation	US$22.5 billion

TTM: trailing 12 months

Shorting BioNTech shares

There are currently 6.7 million BioNTech shares held short by investors – that's known as BioNTech's "short interest". This figure is 13.2% up from 5.9 million last month.

There are a few different ways that this level of interest in shorting BioNTech shares can be evaluated.

BioNTech's "short interest ratio" (SIR)

BioNTech's "short interest ratio" (SIR) is the quantity of BioNTech shares currently shorted divided by the average quantity of BioNTech shares traded daily (recently around 2.4 million). BioNTech's SIR currently stands at 2.75. In other words for every 100,000 BioNTech shares traded daily on the market, roughly 2750 shares are currently held short.

However BioNTech's short interest can also be evaluated against the total number of BioNTech shares, or, against the total number of tradable BioNTech shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case BioNTech's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 BioNTech shares in existence, roughly 30 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable BioNTech shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against BioNTech.

Find out more about how you can short BioNTech stock.

BioNTech share dividends

We're not expecting BioNTech to pay a dividend over the next 12 months.

BioNTech overview

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in developing FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/II trial for prostate cancer; BNT113, which is in Phase I trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116, which is in preclinical trail for non-small cell lung cancer. It also develops individualized neo-antigen specific immunotherapies, such as RO7198457, which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT152 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT212 for pancreatic and other cancers; and next-generation checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops MVT-5873, an IgG1 monoclonal antibody, which is in Phase I/II clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc., Sanofi S.A., Genmab A/S, Genevant Sciences GmbH, Eli Lilly and Company, Bayer AG, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. The company was founded in 2008 and is headquartered in Mainz, Germany.

Frequently asked questions

• What percentage of BioNTech is owned by insiders or institutions?

  Currently 1.257% of BioNTech shares are held by insiders and 4.147% by institutions.

• When does the fiscal year end for BioNTech?

  BioNTech's fiscal year ends in December.

• Where is BioNTech based?

  BioNTech's address is: An der Goldgrube 12, Mainz, Germany, 55131

• What is BioNTech's CUSIP number?

  BioNTech's Committee on Uniform Securities Identification Procedures number is: 09075V102